Synapse

← Salim Yusuf

Papers by Salim Yusuf

Page 15 · newest first

  1. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure PatientsCirculation · 2005
  2. Risk Factors Associated With Myocardial Infarction in AfricaCirculation · 2005
  3. Nutrient estimation from an FFQ developed for a black Zimbabwean populationNutrition Journal · 2005
  4. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE).2005
  5. Predictors of mortality and morbidity in patients with chronic heart failureEuropean Heart Journal · 2005
  6. Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary interventionEuropean Heart Journal · 2005
  7. Effectiveness of Comprehensive Disease Management Programmes in Improving Clinical Outcomes in Heart Failure Patients. A Meta-AnalysisEuropean Journal of Heart Failure · 2005
  8. The nutrition transition in IndiaSouth African Journal of Clinical Nutrition · 2005
  9. Effect of Angiotensin-Converting Enzyme Inhibition on Functional Class in Patients with Left Ventricular Systolic Dysfunction—A Meta-AnalysisEuropean Journal of Heart Failure · 2005
  10. How strong is the evidence for the use of perioperative β blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trialsBMJ · 2005
  11. Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart FailureCirculation · 2005
  12. Routine vs Selective Invasive Strategies in Patients With Acute Coronary SyndromesJAMA · 2005
  13. Development of a semi-quantitative food frequency questionnaire for use in United Arab Emirates and Kuwait based on local foodsNutrition Journal · 2005
  14. Patient Perception of the Effect of Treatment with Candesartan in Heart Failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeEuropean Journal of Heart Failure · 2005
  15. Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary InterventionCirculation · 2005
  16. Impact of Cigarette Smoking in High-Risk Patients Participating in a Clinical Trial. A Substudy from the Heart Outcomes Prevention Evaluation (HOPE) TrialEuropean Journal of Cardiovascular Prevention & Rehabilitation · 2005
  17. Need for expertise based randomised controlled trialsBMJ · 2005
  18. The HOPE (Heart Outcomes Prevention Evaluation) Study and its ConsequencesScandinavian Journal of Clinical and Laboratory Investigation · 2005
  19. Effect of Potentially Modifiable Risk Factors Associated With Myocardial Infarction in 52 Countries (The Interheart Study)Journal of Cardiopulmonary Rehabilitation · 2005
  20. Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomesCanadian Journal of Physiology and Pharmacology · 2005
  21. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE studyEuropean Journal of Cardiovascular Prevention & Rehabilitation · 2004
  22. Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic DysfunctionCirculation · 2004
  23. Randomized clinical trials: Slow death by a thousand unnecessary policies?Canadian Medical Association Journal · 2004
  24. Effect of Candesartan on Cause-Specific Mortality in Heart Failure PatientsCirculation · 2004
  25. Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular DysfunctionCirculation · 2004
  26. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyThe Lancet · 2004
  27. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary SyndromeCirculation · 2004
  28. Principles for National and Regional Guidelines on Cardiovascular Disease PreventionCirculation · 2004
  29. Cardiovascular Complications of Cancer TherapyCirculation · 2004
  30. C-Reactive Protein as a Screening Test for Cardiovascular Risk in a Multiethnic PopulationArteriosclerosis Thrombosis and Vascular Biology · 2004
  31. Cost‐effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long‐term model based on the cure trialJournal of Internal Medicine · 2004
  32. Canadian Trial of Physiological PacingCirculation · 2004
  33. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patientsEuropean Journal of Cardiovascular Prevention & Rehabilitation · 2003
  34. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patientsEuropean Journal of Cardiovascular Prevention & Rehabilitation · 2003
  35. Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary SyndromesCirculation · 2003
  36. New evidence on the importance of the renin???angiotensin system in the treatment of higher-risk patients with hypertensionJournal of Hypertension · 2003
  37. Tackling the growing global burden of atherosclerotic cardiovascular diseases.2003
  38. Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular DiseaseCirculation · 2003
  39. The evolution of the randomized controlled trial and its role in evidence‐based decision makingJournal of Internal Medicine · 2003
  40. Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive HeparinCirculation · 2003
  41. Clinical Features and Contemporary Management of Patients with Low and Preserved Ejection Fraction Heart Failure: Baseline Characteristics of Patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and Morbidity (CHARM) ProgrammeEuropean Journal of Heart Failure · 2003
  42. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) StudyCirculation · 2003
  43. Development of Renal Disease in People at High Cardiovascular RiskJournal of the American Society of Nephrology · 2003
  44. Early and Late Effects of Clopidogrel in Patients With Acute Coronary SyndromesCirculation · 2003
  45. Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) StudyCirculation · 2003
  46. Diagnostic Strategies to Detect Glucose Intolerance in a Multiethnic PopulationDiabetes Care · 2003
  47. Multiple Infections and Subsequent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) StudyCirculation · 2003
  48. The Relationship Between Dysglycemia and Atherosclerosis in South Asian, Chinese, and European Individuals in CanadaDiabetes Care · 2003
  49. Oral Anticoagulant Therapy in Patients with Coronary Artery DiseaseSeminars in Vascular Medicine · 2003
  50. A Lifetime of PreventionCirculation · 2002